Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenstrom Macroglobulinaemia: A Retrospective Real-World Analysis.

ABSTRACT:

Introduction

We retrospectively analysed bortezomib-dexamethasone-rituximab (BDR) combination in patients with Waldenström macroglobulinaemia (WM) in a real world setting.

Methods

A total of 87 patients were included: 49 patients (56%) were treated in frontline, 22 (25%) in second line and 16 (19%) in third or further line settings. A log-rank test was used to compare overall and event-free survival (OS and EFS) whereas a Gray's test was performed to compare cumulative incidence of deaths and relapse (CID and CIR) according to the IPSS-WM groups, MYD88/CXCR4 mutational status and line of therapy.

Results

The overall response rate was 88% with five patients (6%) achieving complete response, 20 (24%) very good partial response, 38 (45%) partial response and 11 (13%) min

SUBMITTER: Hueso T 

PROVIDER: S-EPMC11920810 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature